Using CRISPR-Cas technology to provide accessible testing to developing countries.
In developing countries, maternal mortality due to preeclampsia is greater than 15% compared to 0-1.8% in developped countries.
Every year, in Sub-Saharan Africa more than 40, 500 women die from preeclampsia.
Developing countries do not have the advanced infrastructure found in developed countries. Thus, mothers often do not have access to basic laboratory equipment for preeclampsia diagnosis.
.svg){kind=icon}
.svg){kind=icon}
"The technology behind Helix-B's CRISPR lateral flow tests is very interesting for sure!" – Dr. Fern Tablin, PhD. , professor at University of California Davis, expert in blood lyophilization and cell biology.
Each one of our lateral flow testing kits comes with lyophilized Cas12a protein, primers, amplification reagents, a lateral flow test and small test tubes. Their small component size makes them easy to use and compatible for mass transport.
Helix-B Technologies lateral flow tests can be manufactured for around $17.50, a low cost option viable for mass production.
At Helix-B Technologies, we want to get genetic testing in the hands of every mother. How? We plan to partner with Bill & Melinda Gates Foundation, National Institutes of Health (NIH), and The Red Cross to ensure funding, continued research and distribution of the test, respectively. Additionally, we intend to scale distribution by selling directly to country governments in the region.
